![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DUSP13 |
Gene summary for DUSP13 |
![]() |
Gene information | Species | Human | Gene symbol | DUSP13 | Gene ID | 51207 |
Gene name | dual specificity phosphatase 13 | |
Gene Alias | BEDP | |
Cytomap | 10q22.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q6B8I1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51207 | DUSP13 | HCC1_Meng | Human | Liver | HCC | 1.26e-26 | 1.69e-01 | 0.0246 |
51207 | DUSP13 | S028 | Human | Liver | HCC | 9.54e-10 | 6.20e-01 | 0.2503 |
51207 | DUSP13 | S029 | Human | Liver | HCC | 3.20e-15 | 7.87e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:000647021 | Liver | HCC | protein dephosphorylation | 162/7958 | 281/18723 | 1.91e-07 | 3.46e-06 | 162 |
GO:00434097 | Liver | HCC | negative regulation of MAPK cascade | 98/7958 | 180/18723 | 7.88e-04 | 4.74e-03 | 98 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DUSP13 | SNV | Missense_Mutation | c.352A>G | p.Ile118Val | p.I118V | Q9UII6 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
DUSP13 | SNV | Missense_Mutation | c.658G>A | p.Ala220Thr | p.A220T | Q9UII6 | protein_coding | tolerated(0.41) | benign(0.003) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
DUSP13 | SNV | Missense_Mutation | novel | c.722N>C | p.Leu241Pro | p.L241P | Q9UII6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
DUSP13 | SNV | Missense_Mutation | c.621N>T | p.Glu207Asp | p.E207D | Q9UII6 | protein_coding | deleterious(0) | possibly_damaging(0.618) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
DUSP13 | SNV | Missense_Mutation | c.349C>G | p.Leu117Val | p.L117V | Q9UII6 | protein_coding | deleterious(0) | possibly_damaging(0.827) | TCGA-AY-4071-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DUSP13 | SNV | Missense_Mutation | rs148981646 | c.248N>A | p.Arg83His | p.R83H | Q9UII6 | protein_coding | deleterious(0.03) | probably_damaging(0.92) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DUSP13 | SNV | Missense_Mutation | c.452G>A | p.Gly151Asp | p.G151D | Q9UII6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
DUSP13 | SNV | Missense_Mutation | rs147674959 | c.428N>A | p.Arg143His | p.R143H | Q9UII6 | protein_coding | tolerated(0.14) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DUSP13 | SNV | Missense_Mutation | novel | c.284N>G | p.His95Arg | p.H95R | Q9UII6 | protein_coding | deleterious(0.04) | possibly_damaging(0.705) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
DUSP13 | SNV | Missense_Mutation | rs761243609 | c.239N>T | p.Ser80Leu | p.S80L | Q9UII6 | protein_coding | deleterious(0) | benign(0.066) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |